Conv. Plasma
Nigella Sativa

All famotidine studies
Meta analysis
study COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk ICU time 9% Time to improvement 33% Recovery time 7% Hospitalization time 17% Time to viral- 13% Famotidine  Chowdhury et al.  ICU PATIENTS  RCT Is very late treatment with famotidine beneficial for COVID-19? RCT 208 patients in Bangladesh (August 2020 - April 2021) Faster improvement (p<0.0001) and shorter hospitalization (p=0.013) Chowdhury et al., World J. Clinical Ca.., Aug 2022 Favors famotidine Favors control

Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial

Chowdhury et al., World Journal of Clinical Cases, doi:10.12998/wjcc.v10.i23.8170, NCT04504240
Aug 2022  
  Source   PDF   All   Meta
Famotidine for COVID-19
25th treatment shown to reduce risk in October 2021
*, now known with p = 0.00026 from 30 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
RCT 208 ICU patients in Bangladesh, showing improved recovery with famotidine. Famotidine 40mg (<60kg) or 60mg every 8 hours.
risk of death, 16.1% lower, RR 0.84, p = 0.53, treatment 26 of 104 (25.0%), control 31 of 104 (29.8%), NNT 21.
ICU time, 9.3% lower, relative time 0.91, p = 0.33, treatment 78, control 73.
time to improvement, 32.9% lower, relative time 0.67, p < 0.001, treatment mean 9.53 (±5.0) n=78, control mean 14.21 (±5.6) n=73, time to clinical improvement.
recovery time, 7.3% lower, relative time 0.93, p = 0.14, treatment mean 17.9 (±5.4) n=78, control mean 19.3 (±6.3) n=73, time to symptomatic recovery.
hospitalization time, 17.0% lower, relative time 0.83, p = 0.01, treatment 78, control 73.
time to viral-, 13.0% lower, relative time 0.87, p = 0.002, treatment 78, control 73.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chowdhury et al., 16 Aug 2022, Randomized Controlled Trial, Bangladesh, peer-reviewed, mean age 57.1, 11 authors, study period 1 August, 2020 - 15 April, 2021, trial NCT04504240 (history). Contact:,,
This PaperFamotidineAll
Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial
Abu Taiub Mohammed Mohiuddin Chowdhury, Md Aktar Kamal, Md. Kafil Uddin Abbas, Md Rezaul Karim, Md. Ahsan Ali, Shubhashis Talukder, Hamidullah M Hamidullah Mehedi, Abul Hamid Hassan, Abul Hossain Shahin, Yarui Li, Shuixiang He
World Journal of Clinical Cases, doi:10.12998/wjcc.v10.i23.8170
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online. WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.
Research motivation COVID-19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Thus, clinicians and scientists all over the world are struggling with the treatment of this disease. Besides antiviral drugs, immunosuppressive agents and symptomatic therapy like the H 2 receptor blocker famotidine came to the limelight due to its role in reducing the symptoms of COVID-19 patients. Research objectives To evaluate the role of H 2 receptor blocker "famotidine" in COVID-19 illness. Research methods Research results (1) The recovery (75% in group A and 70% in group B and death (25% in group A and 30% in group B) were found preferable in group A than that in group B; (2) Superior improvement of the computed tomography (CT) chest findings was observed in the famotidine treatment group; (3) Among the group A survivors, the duration of ICU and hospital stays were low; (4) However, the difference between the time to symptomatic recovery, ICU stay duration and the time to clinical failure/death among the groups were not significant, P ≥ 0.05; ( 5 ) Group A achieved a reduction of hospital stay and rapid recovery; ( 6 ) Viral recovery was delayed in the control group; and (7) The Kaplan Meier survival analysis was performed. The difference involving survival among the two study groups did not show any statistical significance (P = 0.989). Research conclusions The famotidine treatment group demonstrated a..
Bozkurt, Bilen, Gastrointestinal symptoms in COVID-19 could be associated with severe lung involvement and increased readmission rates, Eur J Inflamm, doi:10.1177/20587392211048259
Báez-Santos, John, Mesecar, Mielech, Chen et al., Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities, Antiviral Res, doi:10.1016/j.virusres.2014.01.025
Chowdhury, Karim, Mehedi, Shahbaz, Chowdhury et al., Analysis of the primary presenting symptoms and hematological findings of COVID-19 patients in Bangladesh, J Infect Dev Ctries, doi:10.3855/jidc.13692
Chowdhury, Shahbaz, Karim, Islam, Dan et al., A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients, Eurasian J Med Oncol, doi:10.14744/EJMO.2021.16263
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053
Freedberg, Wang, Abrams, Famotidine and Coronavirus Disease 2019, Gastroenterology, doi:10.1053/j.gastro.2020.12.044
Janowitz, Gablenz, Pattinson, Wang, Conigliaro et al., Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut, doi:10.1136/gutjnl-2020-321852
Langtry, Grant, Goa, Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases, Drugs, doi:10.2165/00003495-198938040-00005
Lechien, Chiesa-Estomba, Siati, Horoi, Bon et al., Olfactory and gustatory dysfunctions as a clinical presentation of mildto-moderate forms of the coronavirus disease (COVID-19): a multicenter European study, Eur Arch Otorhinolaryngol, doi:10.1007/s00405-020-05965-1
Malone, Tisdall, Smith, Liu, Huang et al., COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms, Front Pharmacol, doi:10.3389/fphar.2021.633680
Mather, Seip, Mckay, Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, Am J Gastroenterol, doi:10.14309/ajg.0000000000000832
Samimagham, Azad, Haddad, Arabi, Hooshyar et al., The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial, Trials, doi:10.1186/s13063-020-04773-6
Sun, Chen, Hu, Wu, Liang et al., Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients?, Dig Dis Sci, doi:10.1007/s10620-021-06872-z
Xie, Ding, Li, Wang, Guo et al., Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test, J Med Virol, doi:10.1002/jmv.25930
Yousefi, Mashouri, Okpechi, Alahari, Alahari, Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action, Biochem Pharmacol, doi:10.1016/j.bcp.2020.114296
Zheng, Yang, Zhou, Li, Liu et al., Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective, Res Social Adm Pharm, doi:10.1016/j.sapharm.2020.03.012
Zhou, Wang, Lee, Wu, Cheung et al., Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study, Gut, doi:10.1136/gutjnl-2020-323668
{ 'DOI': '10.12998/wjcc.v10.i23.8170', 'ISSN': ['2307-8960'], 'URL': '', 'author': [ { 'affiliation': [], 'family': 'Chowdhury', 'given': 'Abu Taiub Mohammed Mohiuddin', 'sequence': 'first'}, {'affiliation': [], 'family': 'Kamal', 'given': 'Aktar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Abbas', 'given': 'Md. Kafil Uddin', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Karim', 'given': 'Md Rezaul', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ali', 'given': 'Md. Ahsan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Talukder', 'given': 'Shubhashis', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mehedi', 'given': 'H.M. Hamidullah', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Hassan', 'given': 'Hamid', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shahin', 'given': 'Abul Hossain', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Li', 'given': 'Yarui', 'sequence': 'additional'}, {'affiliation': [], 'family': 'He', 'given': 'Shuixiang', 'sequence': 'additional'}], 'container-title': 'World Journal of Clinical Cases', 'container-title-short': 'WJCC', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 7, 25]], 'date-time': '2022-07-25T18:32:43Z', 'timestamp': 1658773963000}, 'deposited': { 'date-parts': [[2022, 7, 25]], 'date-time': '2022-07-25T18:33:35Z', 'timestamp': 1658774015000}, 'indexed': {'date-parts': [[2022, 7, 25]], 'date-time': '2022-07-25T19:11:12Z', 'timestamp': 1658776272546}, 'is-referenced-by-count': 0, 'issue': '23', 'issued': {'date-parts': [[2022, 8, 16]]}, 'journal-issue': {'issue': '23'}, 'link': [ { 'URL': '', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '2060', 'original-title': [], 'page': '8170-8185', 'prefix': '10.12998', 'published': {'date-parts': [[2022, 8, 16]]}, 'published-print': {'date-parts': [[2022, 8, 16]]}, 'publisher': 'Baishideng Publishing Group Inc.', 'reference': [ {'DOI': '10.1002/jmv.25930', 'doi-asserted-by': 'publisher', 'key': 'B1'}, {'DOI': '10.1016/j.sapharm.2020.03.012', 'doi-asserted-by': 'publisher', 'key': 'B2'}, {'DOI': '10.3389/fphar.2021.633680', 'doi-asserted-by': 'publisher', 'key': 'B3'}, {'DOI': '10.1136/gutjnl-2020-321852', 'doi-asserted-by': 'publisher', 'key': 'B4'}, {'DOI': '10.14309/ajg.0000000000000832', 'doi-asserted-by': 'publisher', 'key': 'B5'}, {'DOI': '10.3855/jidc.13692', 'doi-asserted-by': 'publisher', 'key': 'B6'}, {'DOI': '10.1007/s00405-020-05965-1', 'doi-asserted-by': 'publisher', 'key': 'B7'}, { 'key': 'B8', 'unstructured': 'Centers for Disease Control and Prevention. Interim clinical guidance ' 'for management of patients with confirmed coronavirus disease ' '(COVID–19). [cited 5 March 2022]. Available from: ' ''}, {'DOI': '10.14744/EJMO.2021.16263', 'doi-asserted-by': 'publisher', 'key': 'B9'}, {'DOI': '10.2165/00003495-198938040-00005', 'doi-asserted-by': 'publisher', 'key': 'B10'}, {'DOI': '10.1016/j.antiviral.2014.12.015', 'doi-asserted-by': 'publisher', 'key': 'B11'}, {'DOI': '10.1016/j.jmb.2017.04.011', 'doi-asserted-by': 'publisher', 'key': 'B12'}, {'DOI': '10.1016/j.virusres.2014.01.025', 'doi-asserted-by': 'publisher', 'key': 'B13'}, {'DOI': '10.1053/j.gastro.2020.12.044', 'doi-asserted-by': 'publisher', 'key': 'B14'}, {'DOI': '10.1053/j.gastro.2020.05.053', 'doi-asserted-by': 'publisher', 'key': 'B15'}, {'DOI': '10.1177/20587392211048259', 'doi-asserted-by': 'publisher', 'key': 'B16'}, {'DOI': '10.1186/s13063-020-04773-6', 'doi-asserted-by': 'publisher', 'key': 'B17'}, {'DOI': '10.1136/gutjnl-2020-323668', 'doi-asserted-by': 'publisher', 'key': 'B18'}, {'DOI': '10.1016/j.bcp.2020.114296', 'doi-asserted-by': 'publisher', 'key': 'B19'}, {'DOI': '10.1007/s10620-021-06872-z', 'doi-asserted-by': 'publisher', 'key': 'B20'}], 'reference-count': 20, 'references-count': 20, 'relation': {}, 'resource': {'primary': {'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'Role of H<sub>2 </sub>receptor blocker famotidine over the clinical recovery of COVID-19 ' 'patients: A randomized controlled trial', 'type': 'journal-article', 'volume': '10'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop